Semaphorin 4B Promotes Tumor Progression and Associates with Immune Infiltrates in Lung Adenocarcinoma

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2022 Jun 8

PMID 35676688

Authors

Jun Jiang

Yuan Lu

Fang Zhang

Tao Pan

Zhipei Zhang

Yi Wan

Xinling Ren

Rui Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Semaphorins have been found to play important roles in multiple malignancy-related processes. However, the role of Semaphorin 4B (SEMA4B) in lung cancer remains unclear. Here, we aimed to explore the biological functions of SEMA4B in through bioinformatic analysis, in vitro and in vivo assays. In the present study, the possible mechanism by which SEMA4B affected the tumor growth and microenvironment of lung adenocarcinoma (LUAD) were investigated.

Methods: The expression of SEMA4B in LUAD was analyzed by bioinformatic analysis and verified by the immunohistochemistry staining. The prognostic value of SEMA4B in LUAD was investigated using the Kaplan-Meier survival and Cox's regression model. After silencing SEMA4B expression, the functions of SEMA4B in LUAD cells were investigated by in vitro experiments, including CCK-8 and plate clone formation. And the effect of SEMA4B on tumor growth and immune infiltration was explored in C57BL/6 mice tumor-bearing models.

Results: SEMA4B expression was upregulated in LUAD tissues and correlated with later pathological stages and poor prognosis of LUAD patients. Further study found that SEMA4B silencing suppressed the proliferation of lung cancer cells both in vitro and in vivo. Bioinformatic analysis showed that SEMA4B expression was correlated with the increased infiltration of myeloid-derived suppressor cells (MDSCs), T-regs and the decreased infiltration of CD8 T cell in LUAD. Importantly, in vivo study verified that the infiltration of T-regs and MDSCs in tumor microenvironment (TME) of Xenograft tissues was decreased after SEMA4B silencing.

Conclusions: These findings demonstrated SEMA4B might play an oncogenic role in LUAD progression, and be a promising therapeutic target for lung cancer.

Citing Articles

Anti-EGFR ScFv functionalized exosomes delivering LPCAT1 specific siRNAs for inhibition of lung cancer brain metastases.

Jiang J, Lu Y, Chu J, Zhang X, Xu C, Liu S J Nanobiotechnology. 2024; 22(1):159.

PMID: 38589859 PMC: 11000333. DOI: 10.1186/s12951-024-02414-7.

Effects of the SEMA4B gene on hexavalent chromium [Cr(VI)]-induced malignant transformation of human bronchial epithelial cells.

Qin Y, Xu H, Xi Y, Feng L, Chen J, Xu B Toxicol Res (Camb). 2024; 13(2):tfae030.

PMID: 38464415 PMC: 10919774. DOI: 10.1093/toxres/tfae030.

Semaphorins and Their Roles in Breast Cancer: Implications for Therapy Resistance.

Aiyappa-Maudsley R, McLoughlin L, Hughes T Int J Mol Sci. 2023; 24(17).

PMID: 37685898 PMC: 10487980. DOI: 10.3390/ijms241713093.

Semaphorins in immune cell function, inflammatory and infectious diseases.

Thomas R, Yang X Curr Res Immunol. 2023; 4:100060.

PMID: 37645659 PMC: 10461194. DOI: 10.1016/j.crimmu.2023.100060.

Hypoxia Changes Energy Metabolism and Growth Rate in Non-Small Cell Lung Cancer Cells.

Nisar H, Sanchidrian Gonzalez P, Brauny M, Labonte F, Schmitz C, Roggan M Cancers (Basel). 2023; 15(9).

PMID: 37173939 PMC: 10177580. DOI: 10.3390/cancers15092472.

References

Ziegler L, Gerner M, Schmidt R, Trapin D, Steinberger P, Pickl W . Attenuation of canonical NF-κB signaling maintains function and stability of human Treg. FEBS J. 2020; 288(2):640-662. PMC: 7891634. DOI: 10.1111/febs.15361. View

Cagnoni G, Tamagnone L . Semaphorin receptors meet receptor tyrosine kinases on the way of tumor progression. Oncogene. 2013; 33(40):4795-802. DOI: 10.1038/onc.2013.474. View

Nagai H, Sugito N, Matsubara H, Tatematsu Y, Hida T, Sekido Y . CLCP1 interacts with semaphorin 4B and regulates motility of lung cancer cells. Oncogene. 2007; 26(27):4025-31. DOI: 10.1038/sj.onc.1210183. View

Vivian J, Rao A, Nothaft F, Ketchum C, Armstrong J, Novak A . Toil enables reproducible, open source, big biomedical data analyses. Nat Biotechnol. 2017; 35(4):314-316. PMC: 5546205. DOI: 10.1038/nbt.3772. View

Wang H, Zhang X, Ye L, Zhang K, Yang N, Geng S . Insufficient CD100 shedding contributes to suppression of CD8 T-cell activity in non-small cell lung cancer. Immunology. 2020; 160(2):209-219. PMC: 7218665. DOI: 10.1111/imm.13189. View

Peretz L, Besser E, Hajbi R, Casden N, Ziv D, Kronenberg N . Combined shRNA over CRISPR/cas9 as a methodology to detect off-target effects and a potential compensatory mechanism. Sci Rep. 2018; 8(1):93. PMC: 5758708. DOI: 10.1038/s41598-017-18551-z. View

Jian H, Zhao Y, Liu B, Lu S . SEMA4b inhibits MMP9 to prevent metastasis of non-small cell lung cancer. Tumour Biol. 2014; 35(11):11051-6. DOI: 10.1007/s13277-014-2409-8. View

Siegel R, Miller K, Fuchs H, Jemal A . Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1):7-33. DOI: 10.3322/caac.21654. View

Mishra R, Thorat D, Soundararajan G, Pradhan S, Chakraborty G, Lohite K . Semaphorin 3A upregulates FOXO 3a-dependent MelCAM expression leading to attenuation of breast tumor growth and angiogenesis. Oncogene. 2014; 34(12):1584-95. DOI: 10.1038/onc.2014.79. View

10.

Hirsch F, Scagliotti G, Mulshine J, Kwon R, Curran Jr W, Wu Y . Lung cancer: current therapies and new targeted treatments. Lancet. 2016; 389(10066):299-311. DOI: 10.1016/S0140-6736(16)30958-8. View

11.

Jian H, Zhao Y, Liu B, Lu S . SEMA4B inhibits growth of non-small cell lung cancer in vitro and in vivo. Cell Signal. 2015; 27(6):1208-13. DOI: 10.1016/j.cellsig.2015.02.027. View

12.

Bagchi S, Yuan R, Engleman E . Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annu Rev Pathol. 2020; 16:223-249. DOI: 10.1146/annurev-pathol-042020-042741. View

13.

Han L, Zheng C, Wu S . Long non-coding RNA NEAT1 promotes the malignancy of laryngeal squamous cell carcinoma by regulating the microRNA-204-5p/SEMA4B axis. Oncol Lett. 2021; 22(5):802. PMC: 8477075. DOI: 10.3892/ol.2021.13063. View

14.

Sun L, Zhang Z, Yao Y, Li W, Gu J . Analysis of expression differences of immune genes in non-small cell lung cancer based on TCGA and ImmPort data sets and the application of a prognostic model. Ann Transl Med. 2020; 8(8):550. PMC: 7214889. DOI: 10.21037/atm.2020.04.38. View

15.

Onoi K, Chihara Y, Uchino J, Shimamoto T, Morimoto Y, Iwasaku M . Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review. J Clin Med. 2020; 9(5). PMC: 7290914. DOI: 10.3390/jcm9051362. View

16.

Kikutani H, Kumanogoh A . Semaphorins in interactions between T cells and antigen-presenting cells. Nat Rev Immunol. 2003; 3(2):159-67. DOI: 10.1038/nri1003. View

17.

Clavijo P, Friedman J, Robbins Y, Moore E, Smith E, Zauderer M . Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function. Cancer Immunol Res. 2018; 7(2):282-291. PMC: 8326929. DOI: 10.1158/2326-6066.CIR-18-0156. View

18.

Rajabinejad M, Asadi G, Ranjbar S, Afshar Hezarkhani L, Salari F, Gorgin Karaji A . Semaphorin 4A, 4C, and 4D: Function comparison in the autoimmunity, allergy, and cancer. Gene. 2020; 746:144637. DOI: 10.1016/j.gene.2020.144637. View

19.

Jia R, Sui Z, Zhang H, Yu Z . Identification and Validation of Immune-Related Gene Signature for Predicting Lymph Node Metastasis and Prognosis in Lung Adenocarcinoma. Front Mol Biosci. 2021; 8:679031. PMC: 8182055. DOI: 10.3389/fmolb.2021.679031. View

20.

Zhang L, Bai L, Liu X, Liu Y, Li S, Liu J . Factors related to rapid progression of non-small cell lung cancer in Chinese patients treated using single-agent immune checkpoint inhibitor treatment. Thorac Cancer. 2020; 11(5):1170-1179. PMC: 7180579. DOI: 10.1111/1759-7714.13370. View